KEY FEATURES
| Full Name | Tumor Necrosis Factor Related Apoptosis Inducing Ligand |
|---|---|
| Synonym | CD253; TNFSF10; APO2L; Apo2-L; TL2; TRAIL; Tumor Necrosis Factor Ligand Superfamily Member 10; Apo-2 Ligand |
| Assay Type | Sandwich |
| Reactivity | Human |
| Range | 0.15-10ng/mL |
| Sensitivity | 0.06ng/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 100μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Human TRAIL in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human TRAIL. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human TRAIL and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human TRAIL, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human TRAIL. You can calculate the concentration of Human TRAIL in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES

TYPICAL DATA

Human TRAIL ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (ng/mL) | 0.46 | 0.99 | 4.32 | 0.48 | 0.94 | 4.36 |
| Standard deviation | 0.03 | 0.05 | 0.17 | 0.03 | 0.06 | 0.23 |
| CV(%) | 6.96 | 4.71 | 3.92 | 5.98 | 5.93 | 5.17 |
RECOVERY
The recovery of Human TRAIL spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 85-98 | 91 |
| EDTA plasma (n=8) | 84-96 | 90 |
| Cell culture media (n=8) | 87-100 | 93 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human TRAIL in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.

Products associated with TTR ELISA Kits
| RBP4 ELISA Kit | publications with TTR and RBP4 |
| APP ELISA Kit | publications with TTR and APP |
| APOA1 ELISA Kit | publications with TTR and APOA1 |
| APCS ELISA Kit | publications with TTR and APCS |
| FOXA3 ELISA Kit | publications with TTR and FOXA3 |
| CST3 ELISA Kit | publications with TTR and CST3 |
Pathways associated with TTR ELISA Kit
| Amyloids Pathway | Amyloids Pathway |
| Disease Pathway | Disease Pathway |
| Diseases Associated With Visual Transduction Pathway | Diseases Associated With Visual Transduction Pathway |
| Extracellular Matrix Organization Pathway | Extracellular Matrix Organization Pathway |
| FOXA2 And FOXA3 Transcription Factor Networks Pathway | FOXA2 And FOXA3 Transcription Factor Networks Pathway |
| Non-integrin Membrane-ECM Interactions Pathway | Non-integrin Membrane-ECM Interactions Pathway |
| Retinoid Cycle Disease Events Pathway | Retinoid Cycle Disease Events Pathway |
| Retinoid Metabolism And Transport Pathway | Retinoid Metabolism And Transport Pathway |
| Signal Transduction Pathway | Signal Transduction Pathway |
| The Canonical Retinoid Cycle In Rods (twilight Vision) Pathway | The Canonical Retinoid Cycle In Rods (twilight Vision) Pathway |
Diseases associated with TTR ELISA Kit
| Nervous System Diseases | publications with TTR and Nervous System Diseases |
| Amyloidosis, Familial | publications with TTR and Amyloidosis, Familial |
| Amyloid Neuropathies, Familial | publications with TTR and Amyloid Neuropathies, Familial |
| Neoplasms | publications with TTR and Neoplasms |
| Heart Diseases | publications with TTR and Heart Diseases |
| Brain Diseases | publications with TTR and Brain Diseases |
| Liver Diseases | publications with TTR and Liver Diseases |
| Drug Toxicity | publications with TTR and Drug Toxicity |
| Inflammation | publications with TTR and Inflammation |
| Immune System Diseases | publications with TTR and Immune System Diseases |
Organs/Tissues associated with TTR ELISA Kit
| Liver | publications with TTR and Liver |
| Brain | publications with TTR and Brain |
| Heart | publications with TTR and Heart |
| Muscle | publications with TTR and Muscle |
| Kidney | publications with TTR and Kidney |
| Eye | publications with TTR and Eye |
| Skin | publications with TTR and Skin |
| Lung | publications with TTR and Lung |
| Embryonic Tissue | publications with TTR and Embryonic Tissue |
| Pancreas | publications with TTR and Pancreas |